## THE LONDON GAZETTE, 25TH NOVEMBER 1994

Product Licence Number	Сотрану Name	Product Name	Active Ingredients	Indications	Date of Authorisation
				The use of this product is strictly limited to:  (1) Constipation in geriatis: practice and in analgesic induced constipation in the terminully ill in all age groups.  (2) Constipation in cardic failure and coronary thrombosis (conditions in which deflectation	
				must be free of stain). (3) Prophylaxis of analgesic induced constipation in terminally ill cancer patients. POM	
0337/0249	Napp Laboratories Limited	Strong Co-Danthramer Capsules	Danthron BP 37.5 mg Poloxamer 188 NF 500 mg	See PL/0337/0248. POM	19th October 1994
0353/0018	J. Waterhouse and Co. Limited	Fennings Little Healers	Prepared Ipecacuanha BP 20 mg	As an aid to expectoration for coughs associated with colds and catarrah.  GSL	19th August 1994
0353/0019	J. Waterbouse and Co. Limited	Fennings Children's Cooling Powder	Paracciamol EP 50.0 mg	For the treatment of pain arising from teething, headache, uches and pains. Symptomatic relief of feverish colds, influenza and mild feverish conditions.  May be sold or supplied (therwise than by or under the supervision of a pharmacist only whe 1 in packs of not more than 10).  GSL	19th August 1994
0512/0116	Duphar Laboratories Limited	Influvac Sub-Unit	A/Singapore/6/86-like strain (H <sub>1</sub> N <sub>1</sub> ) HSE 15.0 µg A/Shandong/9/93-like strain (H <sub>2</sub> N <sub>2</sub> ) (NIB-31 Rec) HSE 15.0 µg B/Panama/45/90 HSE 15.0 µg	Prophytaxis of Influenza. POM	22nd August 1994
3243/0227	Munro Wholesale Medical Supplies Limited	Zyloric 100 mg	Allopurinel 100.0 mg	Zyloric is indicated for the main clinical manifestations of urate/uric acid deposition. These are gouty arthitis, skin tophi and/or involvement through crystal deposition or store formation. Such clinical manifestations occur in: (diopathic gout, uric acid thinsis, acute uric acid nephropathy, neophistic disease and myeloprolife ative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy; certain enzyme disorders which lead to cver production of urate and involve: hypoxanthine guanine phosphribosyltransferase; (including Leach-Nyhan syndrome), glucose-6-phosphatase (including Leach-Nyhan syndrome), glucose-6-phosphatase (including glycogen storuge disease), phosphoribosyltransferase, gluthathione reductase.  Zyloric is indicated for the management of 2,8-dihydroxadenine (2,8-D'HA) renal stones related to deficier t activity of adenime phosphoribosyltransferase.  Zyloric is indicated for the management of recurrer t calcium oxalste renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.	1st November 1994
3787/0231	Swingward Limited	Tenormim 100 mg Tablets	Atenoloi 100.0 mg	POM Management of Hypertension.	8th November
3787/0319	(t/a Spectrum Marketing) Swingward Limited (t/a Spectrum Marketing)	Cytotec 200 mcg	Misoprostol 200.0 μg	POM Cytotec is indicated for the healing of duodenal ulcer and gastric ulcer including those induced by non- steroidal anti inflammatory drugs (NSAID) in arthitic patients at risk, whilst continuing their NSAID therapy. In addition Cytotec can be used for prophylaxis of NSAID-induced ulcera. POM	1994 8th November 1994
3787/0330	Swingward Limited (Va Spectrum Marketing)	Atrovent Inhaler	Ipratropium Bromide 29.8 mg equvalent to Ipratropium 28.6 mg	POM Atrovent metered dose (nhaler is indicated in the treatment of chronic reversible airws, ye obstruction, particularly in chronic Bronchitis. POM	3rd November 1994